KLAS-TELECOM
18.9.2018 07:02:10 CEST | Business Wire | Press release
Klas Telecom announced today they will supply the TRX Connected Transportation Platform to global engineering house Ikusi for a project to upgrade the passenger information systems onboard Renfe train fleets. Under a Memorandum of Understanding, Klas Telecom’s TRX platform will provide an onboard Wi-Fi infrastructure that improves connectivity to and within the train so that passengers have a better user experience accessing the mobile information and services they need. Klas Telecom and Ikusi have enjoyed a longstanding relationship in which they have worked together to design and develop bespoke solutions to deliver the exacting requirements stipulated by Ikusi’s railway customers.
Ikusi selected Klas Telecom’s TRX R6 as the key component of the onboard passenger Wi-Fi system. The TRX R6 will deliver reliable, high-bandwidth and low-latency connectivity to the train. Another key component of the passenger Wi-Fi system is the software-defined wide area network (SDWAN) feature of the TRX operating system, KlasOS. The KlasOS SDWAN aggregates WAN links and manages multiple wireless bearers in order to provide the train both higher throughput and availability of the offboard WAN link. Klas Telecom’s advanced SDWAN technology leverages any available Internet connection, whether in-station Wi-Fi or 3G/4G LTE connections. The KlasOS SDWAN feature seamlessly routes traffic over uncongested links to ensure that passengers stay connected at all times whether checking e-mails, updating social media, remote working over VPN or making a video call.
“Our partnership with Klas Telecom has gone from strength to strength in recent years,” Ikusi Director of Railway Solutions José Morales said. “We can count on their competence to develop the most appropriate solution to meet the project requirements every time. This Memorandum of Understanding ensures that Ikusi continues to work closer than ever to Klas Telecom, ultimately resulting in greater passenger satisfaction for our customers.”
Brendan Fleming, Klas Telecom Director of Business Development for Transportation, added, “Working with a partner like Ikusi allows us to demonstrate what we do best: developing and supplying the latest cutting-edge technology as part of an onboard Wi-Fi solution, allowing the end customer to provide an optimum passenger experience.”
You can view Klas Telecom’s TRX platform this week at InnoTrans 2018 in Hall 7.1B at Messe Berlin.
More About Klas Telecom
With a background in satellite communications, Klas Telecom is an engineering and design company with over 25 years of experience developing innovative communications solutions for the network edge. Klas Telecom delivers connectivity to communications black spots and austere environments where low size, weight, power and ruggedization are required. The company specializes in integrating enterprise networking capabilities from global IT leaders with in-house hardware and software platforms designed and proven against the most stringent environmental requirements. With over 80% of the company dedicated to technology development, Klas Telecom is able to stay on the forefront of the deployable communications technology. Klas Telecom operates in the public safety, transportation and U.S. and international defense markets. The company employs staff across four offices located in Washington, DC; Herndon, VA; Tampa, FL; and Dublin, Ireland. www.klastelecom.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180917005821/en/
Contact:
Klas Telecom Carrie Sarver Hall | VP of Marketing and Communications 202-288-6342 carrie.hall@klastelecom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom